Extended Data Figure 6: Effects of anti-miR-25 on endogenous miR-25 and SERCA2a in wild-type and Serca2a-null hearts.
From: Inhibition of miR-25 improves cardiac contractility in the failing heart
a–c, Anti-miR-25 or control (scrambled sequence) anti-miRNA was administered intravenously to sham-operated wild-type mice (Sham) or to unoperated Serca2a-cardiomyocyte null (S2a KO) mice38, as for the experiments in Fig. 4 (see Methods). a, Sham-operated animals were injected with anti-miRNAs 1 week after surgery and analysed at 4 weeks. S2a KO animals were injected with 4-OH tamoxifen intraperitoneally for 4 days to delete Serca2a (see Methods), injected with anti-miRNAs 1 week later and analysed 4 weeks later (5 weeks from initial 4-OH-tamoxifen injection). Note that anti-miR-25 decreased endogenous miR-25 levels in sham-operated wild-type and S2a KO mice relative to control-treated animals (n = 3). b, Furthermore, SERCA2a protein levels increased in the anti-miR-25 treated wild-type animals relative to control (n = 3). c, SERCA2a is absent in S2a KO hearts. WT, wild type. In all panels data are represented as mean ± s.e.m. NS, not significant. n = number of biological replicates (all included).
